WO2000028042A1 - Utilisation d'un gene inductible pour l'enzyme cyclo-oxygenase a des fins de reduction de la pression intraoculaire - Google Patents

Utilisation d'un gene inductible pour l'enzyme cyclo-oxygenase a des fins de reduction de la pression intraoculaire Download PDF

Info

Publication number
WO2000028042A1
WO2000028042A1 PCT/US1999/026069 US9926069W WO0028042A1 WO 2000028042 A1 WO2000028042 A1 WO 2000028042A1 US 9926069 W US9926069 W US 9926069W WO 0028042 A1 WO0028042 A1 WO 0028042A1
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
cox
eye
facilitating agent
transformation
Prior art date
Application number
PCT/US1999/026069
Other languages
English (en)
Inventor
Jon C. Nixon
Gustav Graff
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to AU16072/00A priority Critical patent/AU1607200A/en
Publication of WO2000028042A1 publication Critical patent/WO2000028042A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to methods of lowering intraocular pressure (IOP), such as in the treatment of glaucoma.
  • IOP intraocular pressure
  • the invention particularly relates to the use of cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, in such treatment.
  • COX cyclooxygenase
  • Glaucoma is a progressive disease which leads to optic nerve damage and, ultimately, total loss of vision.
  • the causes of this disease have been the subject of extensive studies for many years, but are still not fully understood.
  • the principal symptom of and/or risk factor for the disease is elevated intraocular pressure or ocular hypertension due to excess aqueous humor in the anterior segment of the eye.
  • the anterior segment of the eye consists of anterior and posterior chambers.
  • the anterior chamber lies in front of the iris and contains aqueous humor which helps support the cornea.
  • the posterior chamber lies behind the iris and encompasses the crystallin lens of the eye.
  • IOP elevated intraocular pressure
  • drugs such as beta-blockers and carbonic anhydrase inhibitors, which reduce the production of aqueous humor within the eye, or agents such as miotics and sympathomimetics, which increase the outflow of aqueous humor from the eye.
  • drugs such as beta-blockers and carbonic anhydrase inhibitors, which reduce the production of aqueous humor within the eye, or agents such as miotics and sympathomimetics, which increase the outflow of aqueous humor from the eye.
  • Most types of drugs conventionally used to treat glaucoma have potentially serious side effects.
  • Miotics such as pilocarpine can cause blurring of vision and other visual side effects, which may lead either to decreased patient compliance or to termination of therapy.
  • Systemically administered carbonic anhydrase inhibitors can also cause serious side effects such as nausea, dyspepsia, fatigue, and metabolic acidosis, which side effects can affect patient compliance and/or necessitate the termination of treatment.
  • Another type of drug, beta-blockers have been associated with serious pulmonary side effects attributable to their effects on beta-2 receptors in pulmonary tissue.
  • Sympathomimetics may cause tachycardia, arrhythmia and hypertension.
  • prostaglandins and prostaglandin derivatives have been described in the art as being useful in reducing intraocular pressure.
  • prostaglandin therapy for the treatment of elevated intraocular pressure is attended by undesirable side-effects, such as irritation and hyperemia of varying severity and duration.
  • undesirable side-effects such as irritation and hyperemia of varying severity and duration.
  • Prostaglandins are metabolite derivatives of arachidonic acid. Arachidonic acid in the body is converted to prostaglandin G 2 , which is subsequently converted to prostaglandin H 2 . Other naturally occurring prostaglandins are derivatives of prostaglandin H 2 .
  • a number of different types of prostaglandins have been discovered including A, B, D, E, F,G,I and J-Series prostaglandins (EP 0 561 073 A1).
  • Two naturally-occurring prostaglandins which have been shown to lower IOP are PGF 2 ⁇ (an F-series prostaglandin) and PGE 2 (an E-series prostaglandin) which have the following chemical structures:
  • EP-i EP 2 , EP 3 , and EP 4 (lchikawa, Sugimoto, Negishi, Molecular aspects of the structures and functions of the prostaglandin E receptors, J. Lipid Mediators Cell Signaling, 14:83-87 (1996)).
  • ocular hyperemia such as that attendant to the topical administration of the prostaglandins described above, is mediated by a sensory nerve response on the surface of the eye [1].
  • the prostaglandins PGF 2 ⁇ and PGE 2 are naturally formed by different tissues in the eye and are components of normal aqueous humor. Nevertheless, both are associated with acute inflammation and are considered early mediators of an induced inflammatory response. Still, co- administration of these natural prostaglandins to reduce IOP has been proposed. See, U.S. Patent No. 5,565,492.
  • prostaglandins purporting to avoid or reduce one or more of the side effects attributable to the natural prostaglandins have also been shown to lower IOP by varying degrees. See, for example, U.S. Patent Nos. 5,321 ,128; 5,698,733; 5,700,835; and 5,721 ,273.
  • the cornea which is reportedly capable of producing both PGF 2 ⁇ and PGE 2, appears also to have the ability to convert topically applied PGF 2 ⁇ into PGE 2 to elevate aqueous humor levels of this important prostaglandin.
  • prostaglandins are believed to be produced in all tissues surrounding the anterior chamber of the human eye including the iris/ciliary body, lens epithelial pocket and trabecular meshwork.
  • Constitutive prostaglandin synthesis (non-inducible and providing relatively constant prostaglandin levels in normal aqueous humor) by these tissues may be an important factor in the normal control of IOP, and the loss of prostaglandin synthetic capability at or near the anterior chamber could result in an increase in IOP. Based in part on these observations, it is suggested that tissues in contact with the anterior chamber are likely accustomed to rapid changes in, and probably accommodate to, elevated levels of prostaglandins in aqueous humor.
  • prostaglandins both naturally occurring and synthetic, exogenously applied to the cornea, lower IOP in the glaucoma patient, the availability of a critical concentration of a naturally occurring prostaglandins at or near the "target site(s)" of action is likely diminished over time during the course of the disease. This is one basis for the current prostaglandin therapy for the treatment of glaucoma.
  • the presumed target(s) of prostaglandins are postulated to be related to an altered outflow mechanism associated with possible structural modifications through the uveal-scleral tract or trabecular meshwork.
  • prostaglandins are of secondary importance to that of sustaining the critical concentration of prostaglandins, at or near the target site in the anterior chamber, adequate to lower and control IOP.
  • Current prostaglandin therapies require chronic topical dosing and are, to varying degrees, attended by one or more of the side-effects discussed above.
  • Prostaglandins including both PGF 2 ⁇ and PGE 2 are products of a common biosynthetic pathway, generally known as the arachidonate cascade.
  • the lead enzyme in this pathway cyclooxygenase (COX) utilizes arachidonic acid and other 20 carbon polyunsaturated fatty acids as substrates to form endoperoxides, ultimately leading to the formation of prostaglandins, including PGE 2 and PGF 2 ⁇ .
  • COX exists in at least two isoforms referred to in the literature as COX-1 and COX-2 [2].
  • the COX-1 isoform is considered to be a constitutive enzyme, being relatively non-inducible and remaining at relatively constant levels in the anterior chamber.
  • COX-2 Unlike COX-1 , expression of the COX-2 gene is under the regulation of a number of known effectors including transforming growth factor (TGF-(b)) [3-5], interleukin-1 (IL-1) [3,4,6] and tumor necrosis factor (TNF-( a)) [7]. Expression of the COX-2 gene is particularly responsive to what seems to be a synergistic control of two key cytokines, TGF-(b) and IL-1 [3]. The isolation of the entire COX-2 gene and its ⁇ '-flanking region from a human bacteriophage P1 genomic library has been reported and may be achieved by the methodology of Tazawa et al. [8].
  • the gene containing 10 exons is 7.5 kb in length and is located on human chromosome 1.
  • the transcriptional start site was mapped at 134 bases upstream from the ATG start codon.
  • the nucleotide sequence of the 1.8kb promoter region contains a TATA box and a number of potential regulatory elements including CRE, NF-kappa B, Sp1 and AP2 sites.
  • Studies of the promoter activity showed that the first 460 nucleotides of the ⁇ '-flanking region efficiently drove transcription of a luciferase reporter gene in human umbilical vein endothelial cells upon stimulation [8].
  • the natural promoter region for the COX-2 gene has recently been isolated and sequenced [9], thus permitting the possibility of assembling gene constructs made from this or other effective promoters coupled to the structural gene for the enzyme.
  • the in vitro expression of recombinant human cyclooxygenase isoenzymes has been reported in COS-7 cells transfected with COX cDNA [10] and also in transiently transfected COS-1 cells [11].
  • a recombinant prostaglandin synthesis gene (COX cDNA) has been expressed in vitro in bovine pulmonary artery endothelial cells which resulted in increased intracellular COX protein and increased PGE 2 synthesis.
  • An object of the present invention therefore is to use genetic engineering techniques to provide a COX-based therapy in the treatment of glaucoma thereby avoiding certain limitations and side-effects associated with currently available prostaglandin therapies.
  • the present invention is directed to a method of treating, ameliorating or preventing the occurrence of glaucoma or elevated intraocular pressure (IOP) in the eye of a mammal.
  • the method comprises administering to the eye a therapeutically effective amount of a polynucleotide (including native DNA and cDNA) that encodes a polypeptide having cyclooxygenase activity.
  • a polynucleotide including native DNA and cDNA
  • One method of administering an aforementioned polynucleotide to the eye comprises applying the polynucleotide topically to the exterior of the eye, e.g., to the cornea, under conditions effective to transform the contacted eye tissue.
  • a second method of administration comprises applying to the eye, e.g., by surgical techniques, corneal or other ocular tissues previously transformed with a polynucleotide of the invention.
  • a third method of administration comprises introducing the polynucleotide into the anterior segment of the eye, such as by injecting cells previously transformed with the polynucleotide into the anterior segment.
  • Yet another method of introducing a polynucleotide of the invention into cells or tissues adjoining the anterior chamber or ciliary body of the eye is by providing the polynucleotide as a single or double stranded DNA or RNA of a virus, which is used to transfect ocular tissues either proximal to, or forming the anterior chamber of the eye.
  • an aforementioned polynucleotide can be applied to or introduced into the eye in combination with a transformation facilitating agent, such as a liposome, a cationic lipid, a calcium salt, LIPOFECTIN or any of a number of other agents used for enhancing transfection efficiency in mammalian cells and tissues.
  • a transformation facilitating agent such as a liposome, a cationic lipid, a calcium salt, LIPOFECTIN or any of a number of other agents used for enhancing transfection efficiency in mammalian cells and tissues.
  • the polynucleotide can also be provided as "naked DNA", that is, without a transformation vehicle, without completely compromising transformation efficiency.
  • transformation means altering a cell by the introduction of new or additional genomic material to the cell.
  • the use of a transformation facilitating agent generally enhances transformation of ocular tissue with the polynucleotide by facilitating its passage through the lipid bilayer of the cell membrane. This increases the copy number of COX genes adjacent to
  • a related aspect of the present invention is a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an aforementioned polynucleotide capable of encoding a polypeptide having cyclooxygenase activity.
  • the polynucleotide would encode a full- length COX enzyme, which is expressed by cells transfected with the polynucleotide.
  • the present invention involves a method of treating the eyes of a mammal suffering from a glaucomatous condition, wherein the intraocular pressure (IOP) of the eye is or is likely to become elevated above its "normal” state.
  • the present method can be employed to reduce, or ameliorate elevated IOP and to prevent or impede increases in normal IOP, thereby controlling or slowing the progression of the disease.
  • a method of the present invention comprises administering to an eye of the mammal a therapeutically effective amount of a polynucleotide that encodes a polypeptide having cyclooxygenase activity.
  • the polypeptide can be a full-length COX enzyme, such as COX-1 or COX-2; however, the entire protein is not required as long as the desired COX activity is afforded by the selected polypeptide, e.g., by providing the active site of the enzyme.
  • the active site of the COX-2 enzyme providing cyclooxygenase activity is identified by Hla et al. [6] (the human COX-2 cDNA produced enzymatically active COX).
  • the precise nucleotide sequence employed will generally be a matter of convenience, for instance, due to the availability of a cDNA encoding the full-length protein.
  • Preferred is the human osteosarcoma COX-2 cDNA described in U.S. Patent No. 5,543,297, the disclosure of which is incorporated herein by this reference. Isolation of the human COX-2 genome is also described by Appleby et al. [29].
  • the present invention can be used in veterinary applications, the treated subject will generally be a human being.
  • An aforementioned polynucleotide is typically provided within an expression vector, e.g., as a plasmid or viral nucleic acid.
  • An "expression vector”, as used herein, refers to a vector that facilitates expression of an instant polynucleotide, e.g., by virtue of providing a regulatory sequence (i.e. a promotor) operably linked upstream of the polynucleotide. Examples of such expression vectors are described in U.S. Patent No. 5,543,297, previously incorporated by reference. Additional vectors are described in U.S. Patent No. 5,770,580, the complete disclosure of which is incorporated herein by this reference. U.S. Patent No. 5,770,580 discloses ocular gene therapies, including the control or suppression of glaucoma, but does not disclose the use of COX genes in that regard.
  • a transformation facilitating agent is used in combination with a polynucleotide of the invention so as to increase the amount of polynucleotide in the transformed cells.
  • Suitable transfection and transformation facilitating agents are typically cationic in nature, which increases their affinity for negatively charged nucleic acids.
  • the agents also frequently have lipophilic tails, which increase their affinity for the lipid bilayer, thereby facilitating penetration of the polynucleotide through the cell membrane.
  • the agent is selected so as to enhance the level of transformation that occurs over that obtained by applying a polynucleotide without the facilitating agent.
  • Exemplary agents include liposomes, cationic lipids (including cationic detergents), calcium salts, such as calcium phosphate, dimethylsulfoxide with polycation, as well as commercially available agents such as LIPOFECTIN, DOTMA, DOTAP (Bethesda Research Laboratories; Gaithersburg, MD) and other commercially available cationic agents that facilitate transformation.
  • cationic lipids and methods for intracellular delivery of nucleic acids are described by U.S. Patent No. 5,264,618, the disclosure of which is incorporated herein by reference.
  • a virus can also be considered a transformation facilitating agent, due to its ability to inject nucleic acids into the interior of a cell.
  • Preferred vectors of this type include adenoviruses, which are double-stranded DNA viruses, and retroviruses, as when it is desired to integrate the transforming DNA into the genome of the cell. Exemplary of these methods are those described in U.S. Patent Nos. 5,645,829; 5,656,465; and 5,240,846, the disclosures of which are incorporated herein by reference.
  • the virus can also be used in combination with a cationic molecule, such as polylysine or conjugate thereof, as described by U.S. Patent No. 5,547,932, the disclosure of which is incorporated herein by reference.
  • Still other methods of transforming a cell with an instant polynucleotide include electroporation and microprojectile bombardment as described by Rodriquez [28]. These methods are obviously less desirable for in vivo transformations.
  • the polynucleotide can be applied as "naked DNA", i.e., independent of a transformation facilitating agent. If muscle tissue (e.g. the ciliary muscle) is to be transformed, administration of "naked DNA" is preferred.
  • Administration of an instant composition to the eye can comprise applying an aforementioned polynucleotide directly to the exterior of the eye, i.e., topically.
  • cells of the eye e.g., epithelial cells of the cornea
  • Prostaglandins produced by the cell can permeate adjoining tissue, i.e., the stroma and endothelial layers, and enter the anterior chamber thereby reducing IOP.
  • the polynucleotide is co- administered to the eye with an aforementioned transformation facilitating agent.
  • the polynucleotide can be applied through the action of a virus particle, which transfects the contacted cells, resulting in replication and translation of the polynucleotide.
  • transformation is focused to the cells of the uveal-scleral tract or trabecular meshwork, where the outflow of aqueous humor is most likely to be attenuated in the diseased eye.
  • Another mode of administration comprises directly introducing an aforementioned polynucleotide into the anterior chamber of the eye, e.g. by injection.
  • the polynucleotide can be taken up to some extent by cells surrounding the chamber, with those cells thereby being able to express elevated levels of prostaglandin.
  • the polynucleotide can be provided either as "naked DNA" or in combination with a transformation facilitating agent.
  • the polynucleotide can be provided through a drug delivery device or as part of an artificial lens, e.g., around the perimeter of the lens, and implanted in either the anterior or posterior chamber of the eyes by surgical techniques.
  • Still another mode of administration comprises applying to the eye previously transformed cells or tissue.
  • corneal tissue transformed ex vivo with a polynucleotide of the present invention can be surgically provided either as a corneal transplant or as a "patch" adjacent to the original corneal tissue. Transformation of the corneal tissue with a subject polynucleotide can be performed conventionally, using a transformation facilitating agent as mentioned above, microprojectile bombardment, electroporation, and the like. Sources of corneal tissue are readily available commercially. Alternatively, cells transformed with polynucleotide can be introduced directly into the anterior chamber, e.g., by way of injection.
  • a polynucleotide of the present invention preferably comprises a regulatory sequence that controls transcription of a nucleotide sequence encoding the COX polypeptide.
  • the regulatory sequence is typically linked operably to the nucleotide sequence and is usually located immediately upstream of the encoding sequence. Enhanced expression of a polypeptide having COX activity can be achieved merely by virtue of the increased intracellular copy number of COX-encoding polynucleotides provided according to the present invention.
  • the regulatory sequence can comprise an endogenous COX promoter requiring no exogenous agent to initiate transcription.
  • the regulatory sequence is inducible in the presence of a cytokine, preferably one associated with a glaucomatous condition, or other chemical agent.
  • transcription of the COX encoding sequence can be induced by an endogenous biomolecule, such as transforming growth factor beta (TGFbeta) or by the administration of a suitable drug or chemical modulator, e.g., in the form of eyedrops.
  • TGFbeta transforming growth factor beta
  • a suitable drug or chemical modulator e.g., in the form of eyedrops.
  • regulatory element refers to a DNA sequence typically, but not exclusively, located 5' (upstream) of the transcription initiation site of a structural gene.
  • the regulatory element modulates the specificity and/or level of transcription of the gene.
  • the regulatory element can contain positive and/or negative element(s), which influence the level of expression observed.
  • TGF-beta 1 responsive element in the mouse HSP47 gene has been identified [13].
  • TGF-beta 1 is reported to increase the promoter activity of a region -5.5 kb upstream of the HSP47 gene 4-6 fold, with the regions -3.9 to -2.7 bp and -280 to -50 bp shown to be involved in the activation in response to TGF-beta 1.
  • TGF-beta stimulates PGE 2 production and enhances IL-1 - stimulated PGE 2 production in cultured mouse cells [19].
  • TGF-beta The activation of prostaglandin G/H synthase (PGHS-2 or COX-2) by IL-1 , TGF-alpha, forskolin, and phorbol 13-myristate 12-acetate is also enhanced by TGF-beta [19].
  • the region from -371 to -213 bp of the PGHS-2 promoter reportedly accounts for some 90% of the activity of this promoter[19].
  • a promoter positively activated by TGF-beta 1 is a preferred embodiment of the present invention.
  • tumor necrosis factor alpha (TNF-alpha) is reported to induce COX- 2 [26].
  • NF-IL6 positive regulatory regions at -186 to -131 bp and -512 to -385 bp upstream of the mouse COX-2 gene were identified. These regions contain putative NF-IL6, AP2, and NF kappa B motifs [26]. Additional inducing agents are contemplated for use with the present invention. For example, lipopolysaccharide has been shown to potentiate transcription of COX-2 genes [14, 15, 27]. Interleukin 1 (IL-1) is reported to produce a 10-fold induction of COX-2 [22] and to have a biphasic effect on COX-2 expression , with a NF-IL-6 binding motif being important to achieving maximal promoter activity[16].
  • IL-1 Interleukin 1
  • IL-1 , NF-kappaB, and NF-IL-6 are suggested [16, 25].
  • the dihydroxy bile acids chenodeoxycholate and deoxycholate reportedly increase PGE 2 production 10-fold [17].
  • the compounds 12-0- tetradecanoylphorbol-13-acetate (TPA) [24, 27] and 8-bromo-cAMP reportedly increase PGHS-2 promoter activity [24].
  • Superinduction of IL-1 beta-induced COX-2 by cycloheximide is reported to increase transcription levels [18, 23].
  • Other inducing agents can be readily determined and may be preferred depending on the indications for the patient and a physician's recommendations.
  • Prostaglandin formation according to the present invention may be further enhanced by topical ocular application of an appropriate formulation of a suitable substrate, such as arachidonic acid (20:4) or the ethyl ester of arachidonic acid
  • the concentration of the arachidonic acid or its ethyl ester is preferably in the range of 0.1 micromolar (0.000003%) to 10 micromolar (0.0003%), with a most preferred concentration of 1 micromolar (0.00003%).
  • a suppressing agent i.e., one that can down-regulate the native COX-2 promoter, can be employed whenever over-expression of an instant polynucleotide occurs.
  • suppressing agents include non-steroidal anti- inflammatory drugs (NSAIDS), such as aspirin[24], indomethacin [20], glucocorticoids [21] including dexamethasone [14], phenylarsine oxide [22], actinomycin D [23], and the tyrosine kinase inhibitor herbimycin A [15].
  • NSAIDS non-steroidal anti- inflammatory drugs
  • aspirin[24] indomethacin [20]
  • glucocorticoids including dexamethasone [14], phenylarsine oxide [22], actinomycin D [23], and the tyrosine kinase inhibitor herbimycin A [15].
  • a pharmaceutical composition for use with the present invention is also contemplated.
  • the composition comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of a polynucleotide of the invention, which encodes a polypeptide having COX activity.
  • the polynucleotide comprises an inducible regulatory sequence operably linked to a nucleotide sequence encoding the polypeptide.
  • the polynucleotide can encode a full-length COX enzyme.
  • Suitable carriers include those conventionally available, such as BSS ® and BSS- PLUS ® .
  • an aforementioned transformation facilitating agent can be provided in the composition in order to enhance cell transformation, transfection and expression of polypeptide having COX activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon cette invention, un procédé pour baisser la pression intraoculaire utilise un gène qui code pour une enzyme cyclo-oxygénase (COX). Deux isoformes de COX (COX-1 et COX-2 produisent les prostaglandines PGE2 et PGF2α. Le procédé de traitement consiste à administrer dans l'oeil d'un mammifère qui en a besoin une structure génétique qui code pour un polypeptide possédant l'activité de COX. Dans un mode de réalisation préféré, l'enzyme COX est COX-2. Il est également préférable que le gène puisse être induit avec une petite molécule spécifique ou une cytokine associée avec le début ou la progression du glaucome.
PCT/US1999/026069 1998-11-06 1999-11-04 Utilisation d'un gene inductible pour l'enzyme cyclo-oxygenase a des fins de reduction de la pression intraoculaire WO2000028042A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16072/00A AU1607200A (en) 1998-11-06 1999-11-04 Use of an inducible gene for the enzyme cyclooxygenase to lower intraocular pressure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10741298P 1998-11-06 1998-11-06
US60/107,412 1998-11-06

Publications (1)

Publication Number Publication Date
WO2000028042A1 true WO2000028042A1 (fr) 2000-05-18

Family

ID=22316536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026069 WO2000028042A1 (fr) 1998-11-06 1999-11-04 Utilisation d'un gene inductible pour l'enzyme cyclo-oxygenase a des fins de reduction de la pression intraoculaire

Country Status (2)

Country Link
AU (1) AU1607200A (fr)
WO (1) WO2000028042A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040720A1 (fr) * 1995-06-07 1996-12-19 University Of Rochester Prostaglandine h-synthetase-2 des mammiferes
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5770580A (en) * 1992-04-13 1998-06-23 Baylor College Of Medicine Somatic gene therapy to cells associated with fluid spaces

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770580A (en) * 1992-04-13 1998-06-23 Baylor College Of Medicine Somatic gene therapy to cells associated with fluid spaces
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
WO1996040720A1 (fr) * 1995-06-07 1996-12-19 University Of Rochester Prostaglandine h-synthetase-2 des mammiferes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WAX ET AL: "A rationale for gene targeting in glaucoma therapy", J. OCUL. PHARMACOL., vol. 10, no. 1, 1994, pages 403 - 410, XP000891389 *
WU ET AL.: "injury-coupled induction of endothelial eNOS and COX-2 Genes: a paradigm for thromboresistant Gene Therapy", PROC. ASSOC. AM. PHYSICIANS, vol. 110, no. 3, 1998, pages 163 - 170, XP000891324 *

Also Published As

Publication number Publication date
AU1607200A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
EP1620123B1 (fr) Modification genetique de regions ciblees du systeme de conduction cardiaque
Jacobson et al. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis
CA2904164C (fr) Mir-204 et mir-211 et leurs utilisations
Klausner et al. Corneal gene therapy
US20050220768A1 (en) Materials and methods for treating ocular-related disorders
JP6220785B2 (ja) 被験者における眼疾患の処置のための方法および薬学的組成物
US20240336925A1 (en) Riboswitch modulated gene therapy for retinal diseases
US20160166532A1 (en) Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis
WO2010097800A1 (fr) Combinaison synergique de composés bioactifs pour diminuer la pression intraoculaire
US20050260180A1 (en) Materials and methods for treating vascular leakage in the eye
US7943590B2 (en) Compositions and methods for treating ophthalmic disorders
US20240156638A1 (en) Devices and methods for electrotransfer
WO2000028042A1 (fr) Utilisation d'un gene inductible pour l'enzyme cyclo-oxygenase a des fins de reduction de la pression intraoculaire
US10011837B2 (en) SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP2893018B1 (fr) Arnsi et leur utilisation dans des méthodes et des compositions pour le traitement et/ou la prévention d'états de l' oeil
EP1638591A1 (fr) Agonistes des slrp de classe iii servant a reduire la formation de vaisseaux sanguins
US20110305710A1 (en) Novel compounds for the treatment of glaucoma or ocular hypertension
Anzai et al. Laser Photocoagulation and, to a Lesser Extent, Photodynamic Therapy Target and Enhance Adenovirus Vector–Mediated Gene Transfer in the Rat Retina

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09445168

Country of ref document: US

ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16072

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase